solid tumors and hematologic neoplasia C00-C97
Conditions
Interventions
Group 1: In this registry, clinical data of patients presenting at the molecular tumor board will be documented together with any subsequent treatment information. A basic clinical data set has been d
Sponsors
Universitätsklinikum Schleswig-Holstein, Lübeck Klinik für Hämatologie und Onkologie
Eligibility
Sex/Gender
All
Age
18 Years to 199 Years
Inclusion criteria
Inclusion criteria: Referral to the molecular tumor board
Exclusion criteria
Exclusion criteria: informed consent not signed
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of the potential benefit of presenting to the Molecular Tumor Board when no therapy option according to clinical guidelines remains/ exists. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Determination of the rate of therapy-relevant molecular markers associated with the molecular diagnostic method used. - Documentation of previously undescribed aberrations within and across tumor entities. - Documentation of the frequency of previously known driver mutations in rare tumor entities. - Gaining knowledge through documentation of therapy response and outcome of individual healing attempts as a basis for therapy recommendations in future cases with similar initial situation. | — |
Countries
Germany
Contacts
Public ContactStephanie Fliedner
Universitätsklinikum Schleswig-Holstein Universitäres Cancer Center Schleswig-Holstein
Outcome results
None listed